Literature DB >> 28470113

Nebulized drug delivery in respiratory medicine: what does the future hold?

John N Pritchard1.   

Abstract

In the later half of the 20th century, nebulized therapy was in decline, but in the 21st century the prospects for the expanded use of nebulized therapy within respiratory medicine look bright. The advent of mesh nebulizers, which combine the universal applicability of the nebulizer in the treatment of all respiratory patients with the convenience of portable inhaler use, is ideally timed to capitalize on the forecast of increased numbers of patients who will require nebulized therapy in the future. This special report will highlight some of the opportunities that the development of mesh nebulizers presents in the field of respiratory medicine.

Entities:  

Keywords:  adherence; breath activation; ease of use; jet; mesh; nebulizer; technique

Mesh:

Substances:

Year:  2017        PMID: 28470113     DOI: 10.4155/tde-2017-0015

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  3 in total

1.  Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials.

Authors:  Gary T Ferguson; Gregory Feldman; Krishna K Pudi; Chris N Barnes; Edmund J Moran; Brett Haumann; Srikanth Pendyala; Glenn Crater
Journal:  Chronic Obstr Pulm Dis       Date:  2019-04-09

2.  Evaluation of Aerosol Therapy during the Escalation of Care in a Model of Adult Cystic Fibrosis.

Authors:  Elena Fernández Fernández; Mary Joyce; Andrew O'Sullivan; Ronan MacLoughlin
Journal:  Antibiotics (Basel)       Date:  2021-04-21

3.  Aerosol Characteristics and Physico-Chemical Compatibility of Combivent® (Containing Salbutamol and Ipratropium Bromide) Mixed with Three Other Inhalants: Budesonide, Beclomethasone or N-Acetylcysteine.

Authors:  Rui Zhang; Junhua Hu; Liangjun Deng; Sha Li; Xi Chen; Fei Liu; Shanping Wang; Khaja Shameem Mohammed Abdul; Huimin Beng; Wen Tan
Journal:  Pharmaceutics       Date:  2020-01-17       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.